Search

Search Bar
24/02/2025 Evaluation of cerebrospinal fluid levels of VAMP-2 and SNAP-25 in a dementia with Lewy bodies clinical cohort stratified by Alzheimer's pathophysiological biomarkers
González, AC, Goossens, J, Campuzano, EV, Sala, I, Sánchez-Saudinós, MB, Rodríguez-Baz, I, Lidón, L, Perlaza, D, Bejanin, A, Haapasalo, A, Fortea, J, Alcolea, D, Lleo, A, Vanmechelen, E, Belbin, O. Evaluation of cerebrospinal fluid levels of VAMP-2 and SNAP-25 in a dementia with Lewy bodies clinical cohort stratified by Alzheimer's pathophysiological biomarkers. Alzheimers Research & Therapy. 2025; 17(1)DOI:10.1186/s13195-025-01685-y. PMID:39994784. IF:7.600(Q1/1D).
27/08/2024 Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome
Zsadanyi, SE, Morcillo-Nieto, AO, Aranha, MR, Aragón, I, Arriola-Infante, JE, Vaqué-Alcázar, L, Montal, V, Pegueroles, J, Arranz, J, Rodríguez-Baz, I, Blesa, LM, Videla, L, Barroeta, I, Soriano, LD, Benejam, B, Fernández, S, Hernandez, AS, Bargallo, N, González-Ortiz, S, Giménez, S, Alcolea, D, Belbin, O, Lleó, A, Fortea, J, Carmona-Iragui, M, Bejanin, A. Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome. NEUROLOGY. 2024; 103(4)DOI:10.1212/WNL.0000000000209676. PMID:39074338. IF:8.500(Q1/1D).
18/07/2024 Reply to: Challenges to identifying risk versus protective factors in Alzheimer's disease
Fortea, J, Vaque-Alcazar, L, Pegueroles, J, Alcolea, D, Belbin, O, Dols-Icardo, O, Videla, L, Gispert, JD, Suarez-Calvet, M, Johnson, SC, Sperling, R, Bejanin, A, Lleo, A, Montal, V. Reply to: Challenges to identifying risk versus protective factors in Alzheimer's disease. NATURE MEDICINE. 2024; 30(11)DOI:10.1038/s41591-024-03159-4. PMID:39025967. IF:50.000(Q1/1D).
29/06/2024 APP dyshomeostasis in the pathogenesis of Alzheimer's disease: implications for current drug targets
Sirisi, S, Sánchez-Aced, E, Belbin, O, Lleó, A. APP dyshomeostasis in the pathogenesis of Alzheimer's disease: implications for current drug targets. Alzheimers Research & Therapy. 2024; 16(1)DOI:10.1186/s13195-024-01504-w. PMID:38951839. IF:7.600(Q1/1D).
01/06/2024 miR-519a-3p, found to regulate cellular prion protein during Alzheimer 's disease pathogenesis, as a biomarker of asymptomatic stages
Jácome, D, Cotrufo, T, Andrés-Benito, P, Lidón, L, Martí, E, Ferrer, I, del Río, JA, Gavín, R. miR-519a-3p, found to regulate cellular prion protein during Alzheimer 's disease pathogenesis, as a biomarker of asymptomatic stages. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2024; 1870(5)DOI:10.1016/j.bbadis.2024.167187. PMID:38653354. IF:4.200(Q1/2D).
06/05/2024 APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease
Fortea, J, Pegueroles, J, Alcolea, D, Belbin, O, Dols-Icardo, O, Vaqué-Alcázar, L, Videla, L, Gispert, JD, Suárez-Calvet, M, Johnson, SC, Sperling, R, Bejanin, A, Lleó, A, Montal, V. APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease. NATURE MEDICINE. 2024; DOI:10.1038/s41591-024-02931-w. PMID:38710950. IF:50.000(Q1/1D).